CONFLICT OF INTEREST
cancer
CANCER
Kohei Shitara reports grants and personal fees from Astellas Pharma, Eli Lilly and Company, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical and Merck Pharmaceutical; grants from Dainippon Sumitomo Pharma, Chugai Pharma, Medi Science and Eisai; and personal fees from Bristol Myers Squibb, Takeda Pharmaceuticals, Pfizer, Novartis, AbbVie, Yakult, GlaxoSmithKline, Amgen and Boehringer Ingelheim. Ming Lei reports employment with Bristol Myers Squibb and ownership of stock in Bristol Myers Squibb. Mingshun Li reports employment with Bristol Myers Squibb. Tian Chen reports holding a patent to combination therapy with anti‐IL‐8 antibodies and anti‐PD‐1 antibodies for treating cancer. Lin Shen reports grants from Beijing Xiantong Biomedical Technology Co. Ltd, Qilu Pharmaceutical Co. Ltd, Zaiding Pharmaceutical (Shanghai) Co. Ltd, Jacobio Pharmaceuticals Co. Ltd, Beihai Kangcheng (Beijing) Medical Technology Co. Ltd and Boehringer Ingelheim; and consulting fees from Harbor BioMed and Merck. All other authors declare no competing interests.